Tamoxifen treatment increases the risk of breast cancer patients developing endometrial cancer, say Finnish researchers.
The odds ratio (OR) for endometrial cancer following tamoxifen therapy in breast cancer patients, adjusted for significant cofactors, is 2.9. It is especially high, at 9.5, after a lag of more than five years in tamoxifen used for palliative treatment of advanced breast cancer.
Investigators from the Finnish Cancer Registry in Helsinki and the University of Tampere note the risk increase is slightly higher in patients who were younger than 55 years at initiation of tamoxifen therapy.
Risk was more pronounced in patients with well-differentiated endometrial cancer than in those with clinical grades 2 or 3 cancers. They note that the OR related to adjuvant tamoxifen treatment reached its maximum two to five years after therapy initiation.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!